1-20 of 67
Christopher P Fox
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael J. Dickinson, Christopher P. Fox, Brad Kahl, Alex F. Herrera, Georg Lenz, Yuqin Song, Rong Tao, Qingqing Cai, Tae Min Kim, Michelle Doral, Derrick Kaufman, Leonardo Roque Pereira, Aurelien Berthier, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 1718.1.
https://doi.org/10.1182/blood-2024-194000
Published: 2024
Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef
Journal: Blood
Blood (2024) 144 (Supplement 1): 7614.
https://doi.org/10.1182/blood-2024-207898
Published: 2024
Journal Articles

Delays to Diagnosis of Peripheral T-Cell Lymphoma and Clinical Utility of Molecular Profiling: A UK Multicentre Real-World Study

Jesca Boot, Elizabeth Nelmes, Findlay Bewicke-Copley, Krushika Paleja, Emily Davenport, Ross Henderson, William Hann, Xiao-Yin Zhang, Hannah Bielby, Harshita Goradia, Naim Rahimi, Amjad Hmaid, Rumman Fatima Nizam, Imogen Welding, Vivek Radhakrishnan, Callum Harris, Danielle Monteil, Andrew Clear, Maria Calaminici, Paul Greaves, Andrew J. Davies, Graham P. Collins, Matthew R Wilson, Jeffery Smith, Christopher P Fox, Wendy Osborne, Lucy Cook, Matthew Ahearne, Kate Cwynarski, John G. Gribben, Jessica Okosun
Journal: Blood
Blood (2024) 144 (Supplement 1): 4445.
https://doi.org/10.1182/blood-2024-205820
Published: 2024
Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz
Journal: Blood
Blood (2024) 144 (Supplement 1): 3061.
https://doi.org/10.1182/blood-2024-203577
Published: 2024
Journal Articles

Multi-Modal Analysis Reveals the Differences between Double Expressor and Non-Double Expressor Primary Central Nervous System Lymphomas

Edward Poynton, Esraa Jamal, Findlay Bewicke-Copley, William Lavelle, Lucy Pickard, Andrew Clear, Maria Calaminici, Christopher P Fox, Jessica Okosun
Journal: Blood
Blood (2024) 144 (Supplement 1): 2965.
https://doi.org/10.1182/blood-2024-209747
Published: 2024
Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Talha Munir, Abraham Mullasseril Varghese, Adrian Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankara Paneesha, Christopher P Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, Prof. John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Anna Hockaday, David A. Cairns, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, David Stones, Nichola McWhirter, Surita Dalal, Andrew Rawstron, Piers Patten, Peter Hillmen
Journal: Blood
Blood (2024) 144 (Supplement 1): 585.
https://doi.org/10.1182/blood-2024-211449
Published: 2024
Journal Articles

Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study

Gareth P. Gregory, Jeremy S. Abramson, Hui-Qiang Huang, Qing-Yuan Zhang, Matthew Ku, Dok Hyun Yoon, Christopher P. Fox, Haifaa Abdulhaq, William Townsend, Joan Ashby, Alana Harris, Victor Orellana-Noia, Stephen Simko, Martine Kallemeijn, Richard Ta, James Relf, Huang Huang, Linda Lundberg, Huilai Zhang
Journal: Blood
Blood (2024) 144 (Supplement 1): 5132.
https://doi.org/10.1182/blood-2024-198424
Published: 2024
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications

Euan Haynes, Kushani Ediriwickrema, Sarah Lawless, Kevin Joyce, Matthew Wells, Jeffrey Smith, Kim Linton, Anna Santarsieri, George Follows, John Willan, Robert Osborn, Matthew R Wilson, Pamela McKay, Mahina Baloch, Rory McCulloch, Mary Gleeson, David Wrench, David Foldes, Edward Kanfer, Kyaw Zin Maw, Andrea Kuhnl, Matthew Ahearne, Mary Owen, Jane Norman, Ravindu De Silva, Nimish Shah, Harriet Ambrose, Christopher P. Fox, Janine Qasim, Graham P. Collins, Martha Vickers, David Tucker, Li Yuan Chan, Sunil Iyengar, Dima el-Sharkawi, Rebecca Auer, Catherine Cox, Hwai Jing Hiew, Andrew J. Davies, Philippa Kelsey, David John Lewis, Abigail Martin, Gavin Preston, Dominic J. Culligan, Angus Broom, William Wilson, Wendy Osborne, William Townsend
Journal: Blood
Blood (2024) 144 (Supplement 1): 3100.
https://doi.org/10.1182/blood-2024-203781
Published: 2024
Journal Articles

Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial

Clinical Trials & Observations
Sridhar Chaganti, Shanna Maycock, Graham McIlroy, Aimee Jackson, Rebecca Bishop, Sarah Johnson, Edward Kanfer, Shireen Kassam, Kate Cwynarski, David Wrench, Arvind Arumainathan, Christopher P. Fox, Rod Johnson, Pam McKay, Shankara Paneesha, Clare Rowntree, Constantine Balotis, Graham P. Collins, Andrew Davies, Josh Wright, Sarah Burns, Arian Laurence, Keith Wheatley, Tobias Menne
Journal: Blood
Blood (2024) 144 (4): 392–401.
https://doi.org/10.1182/blood.2024023847
Published: 2024
Includes: Supplemental data
Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Clinical Trials & Observations
Pietro R. Di Ciaccio, Mark N. Polizzotto, Kate Cwynarski, Alina S. Gerrie, Catherine Burton, Mark Bower, John Kuruvilla, Silvia Montoto, Pam McKay, Christopher P. Fox, Samuel Milliken, Awachana Jiamsakul, Wendy Osborne, Graham P. Collins, Kate Manos, Kim M. Linton, Sunil Iyengar, Shireen Kassam, Michelle Poon Limei, David Kliman, Nicole Wong Doo, Anne-Marie Watson, Pasquale Fedele, Costas K. Yannakou, Stewart Hunt, Matthew Ku, Laurie H. Sehn, Alexandra Smith, Hanna Renshaw, Alice Maxwell, Qin Liu, Rageshri Dhairyawan, Graeme Ferguson, Keir Pickard, Daniel Painter, Nisha Thakrar, Kevin W. Song, Nada Hamad
Journal: Blood
Blood (2024) 143 (2): 152–165.
https://doi.org/10.1182/blood.2023021348
Published: 2024
Includes: Supplemental data
Journal Articles

Combining BCL-XL Inhibition with Brentuximab Vedotin to Overcome Chemoresistance in EBV-Related T/NK Lymphoma

Alexander Glover, Christopher P. Fox, Claire Shannon-Lowe
Journal: Blood
Blood (2023) 142 (Supplement 1): 5784.
https://doi.org/10.1182/blood-2023-181703
Published: 2023
Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Peter Hillmen, David Allan Cairns, Adrian John Clifton Bloor, David Allsup, Kate Cwynarski, Andrew Pettitt, Shankaranarayana Paneesha, Christopher P. Fox, Toby A. Eyre, Francesco Forconi, Nagah Elmusharaf, Ben Kennedy, John G. Gribben, Nicholas Pemberton, Oonagh Sheehy, Gavin Preston, Anna Schuh, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sean Girvan, Sue Bell, Julia Brown, Nichola Webster, Surita Dalal, Ruth M de Tute, Andrew Rawstron, Piers EM Patten, Talha Munir
Journal: Blood
Blood (2023) 142 (Supplement 1): 631.
https://doi.org/10.1182/blood-2023-178298
Published: 2023
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando Lopez-Guillermo, Thomas Gastinne, Andreas Viardot, William Townsend, Naseer Qayum, Martin Barrett, Derrick Kaufman, Chun Wu, Ronald McCord, Pauline Baumlin, Patrick Kimes, Franck Morschhauser
Journal: Blood
Blood (2023) 142 (Supplement 1): 3085.
https://doi.org/10.1182/blood-2023-174081
Published: 2023
Journal Articles

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Alexander Glover, Mark Bishton, Matthew Ahearne, Kaljit Bhuller, Steve Jones, Graham P. Collins, Lindsay George, Conal McConville, Allister Foy, Catherine Hildyard, Catherine Moore, Christopher P. Fox, Claire Shannon-Lowe
Journal: Blood
Blood (2023) 142 (Supplement 1): 3660.
https://doi.org/10.1182/blood-2023-182151
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Jehan Dupuis, Kunihiro Tsukasaki, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara, Nicolas Daguindau, René-Olivier Casasnovas, Sylvia Snauwaert, Rémy Gressin, Christopher P. Fox, Francesco Annibale d'Amore, Philipp B. Staber, Argyrios Gkasiamis, Mitsufumi Nishio, Luc-Matthieu Fornecker, Marie-Helene Delfau, Nouhoum Sako, Sebastien Mule, Laurence De Leval, Philippe Gaulard, Francois Lemonnier
Journal: Blood
Blood (2022) 140 (Supplement 1): 2310–2312.
https://doi.org/10.1182/blood-2022-156789
Published: 2022
Journal Articles

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson, Nilanjan Ghosh, Armando Santoro, Antonio Pinto, Francesc Bosch, Christopher P. Fox, Armando López-Guillermo, Claudia Carlucci, Chun Wu, Kathryn Humphrey, Pauline Baumlin, Martin Barrett, Naseer Qayum, Franck Morschhauser
Journal: Blood
Blood (2022) 140 (Supplement 1): 1775–1777.
https://doi.org/10.1182/blood-2022-157732
Published: 2022
Journal Articles

Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Grzegorz S. Nowakowski, John M. Burke, Christopher P. Fox, Marek Trneny, Annalisa Chiappella, Maeve Waldron-Lynch, Steve Wagner, Alok Pachori, Georg Lenz
Journal: Blood
Blood (2022) 140 (Supplement 1): 6618–6620.
https://doi.org/10.1182/blood-2022-155995
Published: 2022